Efficacy of Waj in premenstrual syndrome: A randomized placebo-controlled trial

Diagnosed cases of premenstrual syndrome fulfilling the inclusion criteria will be randomly allocated to the test and control groups. Written informed consent will be obtained from the participants. Participants and the researcher will be blinded in the study, and blinding will be done by third person. The research drug will be given to the participants in capsule form during the luteal phase of the menstrual cycle for 3 consecutive cycles. Participants will be followed every month, 10 days prior to menstruation during treatment and once after menstruation following the completion of treatment. Reduction in VAS and PMTS scores will be assessed during the trial.